Search Results for 'progression months'

progression months published presentations and documents on DocSlides.

CUPISCO trial Tania Tillett

CUPISCO trial Tania Tillett

by wilson

Royal United Hospital. CUPSICO. A . PHASE II, RAND...

Module 12: Gynecologic Cancers

Module 12: Gynecologic Cancers

by broadcastworld

Paula J Anastasia, RN, MN, AOCN. Kathleen Moore, M...

Meaningful Clinical Changes in Alzheimer Disease Measured with the iADRS and Illustrated using the

Meaningful Clinical Changes in Alzheimer Disease Measured with the iADRS and Illustrated using the

by summer

Wessels et . al, . Neurology: Clinical Practice . ...

Analysis of Sustained MRD-Negativity and Progression-Free Survival of Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma Additional Data From Planned Interim Analysis of the GMMG-CONCEPT Trial

Analysis of Sustained MRD-Negativity and Progression-Free Survival of Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma Additional Data From Planned Interim Analysis of the GMMG-CONCEPT Trial

by ayaan

Progression-Free Survival of Isa-. KRd. in High-R...

A PCP’s Guide to CKD Screening and Delaying Progression

A PCP’s Guide to CKD Screening and Delaying Progression

by luanne-stotts

Learning Objectives. Utilize appropriate screenin...

Jon Trent, MD, PhD Professor of Medicine

Jon Trent, MD, PhD Professor of Medicine

by jane-oiler

Sarcoma . Medical Oncology. The University of . M...

Student Progression

Student Progression

by calandra-battersby

John Kirby. Graduate School. Faculty of Medical S...

Progression Monitoring

Progression Monitoring

by stefany-barnette

. Director of Postgraduate Studies. School . of...

Progression of romantic relationships/How to avoid falling

Progression of romantic relationships/How to avoid falling

by jane-oiler

Meeting each. First and Third Monday of every mon...

Molecular Lessons Learnt from Clinical Trials in the Last Decade

Molecular Lessons Learnt from Clinical Trials in the Last Decade

by altigan

Andrew X. Zhu, MD, PhD. Harvard Medical School. Ma...

Updates on T-cell lymphoma

Updates on T-cell lymphoma

by grace3

Dr. Stefan K. Barta. University of Pennsylvania, U...

Median PFS: 2.6 months (95% CI, 1.7-3.5)

Median PFS: 2.6 months (95% CI, 1.7-3.5)

by ceila

Median PFS: 1.4 months (95% CI, 1.2-1.6) . Median ...

FREEDOMS II TRIAL

FREEDOMS II TRIAL

by lois-ondreau

Study Design. 24-month, RCT of . fingolimod. 0.5...

Recurrent Follicular Lymphoma

Recurrent Follicular Lymphoma

by sherrill-nordquist

With a Short First Remission:. How Aggressive Sho...

by phoebe-click

. Highlights from the Annual Clinical Meeting. G...

BELLE-3: A Phase III Study of

BELLE-3: A Phase III Study of

by faustina-dinatale

Buparlisib. and . Fulvestrant. in Postmenopausa...

Managing Advanced Renal Cell

Managing Advanced Renal Cell

by debby-jeon

Carcinoma: Balancing . Efficacy with Quality of L...

Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

by olivia-moreira

Jointly provided by ...

Endocrine resistance: molecular pathways and rational development of targeted therapies

Endocrine resistance: molecular pathways and rational development of targeted therapies

by spottletoefacebook

Grazia Arpino. Università di Napoli Federico II. ...

Nouveautés dans le CBNPC métastatique

Nouveautés dans le CBNPC métastatique

by vizettan

Celine Mascaux, MD, . PhD. Multidisciplinary . Onc...

Please note, these are the actual

Please note, these are the actual

by pinperc

video-recorded proceedings from the . live CME eve...

Disease Progression and Pathogenesis in Congenital Myotonic Dystrophy

Disease Progression and Pathogenesis in Congenital Myotonic Dystrophy

by blanko

Nicholas Johnson, MD. Assistant Professor of Neuro...

Improving long-term outcomes in PAH:

Improving long-term outcomes in PAH:

by reese

Time matters!. Janssen-sponsored virtual symposium...

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref

by willow

Meletios Dimopoulos,. 1. Hang Quach,. 2. Maria-V...

Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in m

Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in m

by felicity

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor...

Module 6: Prostate Cancer

Module 6: Prostate Cancer

by payton

Victoria . Sinibaldi. , RN, MS, CS, CANP, BC. Dani...

Targeting EGFR Exon 20 insertions

Targeting EGFR Exon 20 insertions

by unita

Gregory J. Riely. November 2021. What about those ...